Cargando…
Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
This cross-sectional study estimates all US Food and Drug Administration anticancer approvals in recent years and evaluates if an association exists between their cost and efficacy.
Autores principales: | Miljković, Miloš D., Tuia, Jordan E., Olivier, Timothée, Haslam, Alyson, Prasad, Vinay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623474/ https://www.ncbi.nlm.nih.gov/pubmed/36315136 http://dx.doi.org/10.1001/jamainternmed.2022.4924 |
Ejemplares similares
-
Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021) -
Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021) -
Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers
por: Haslam, Alyson, et al.
Publicado: (2023) -
Scoping Review of Published Oncology Meta-analyses in High-Impact Oncology Journals
por: Haslam, Alyson, et al.
Publicado: (2023) -
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)
por: Jenei, Kristina, et al.
Publicado: (2022)